JMP Securities Reiterates Market Outperform on Ocular Therapeutix, Maintains $24 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jonathan Wolleben has reiterated a Market Outperform rating on Ocular Therapeutix (NASDAQ:OCUL), maintaining a $24 price target. This reaffirmation highlights the analyst's positive outlook on the company's stock.
March 13, 2024 | 3:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JMP Securities analyst Jonathan Wolleben reaffirmed a Market Outperform rating on Ocular Therapeutix, with a maintained price target of $24, indicating a positive outlook on the stock.
The reiteration of a Market Outperform rating and the maintenance of a $24 price target by a JMP Securities analyst could lead to increased investor confidence in Ocular Therapeutix. This positive analyst outlook is likely to have a favorable impact on the stock's short-term price movement, as it suggests the company's future prospects are strong.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100